• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by iBio Inc.

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email
    SC 13G 1 d893918dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    IBIO, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    451033708

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

    Evan K. Hall, Esq.

    Haynes and Boone, LLP

    2801 N. Harwood Street, Suite 2300

    Dallas, Texas 75201

    (214) 651-5000

     

     

     


    SCHEDULE 13G

    CUSIP No. 451033708

     

     1   

     Names of Reporting Persons

     

     Ikarian Capital, LLC

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     Sec Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     599,913 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     599,913 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     599,913 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

     ☐

    11  

     Percent of class represented by amount in row (9)

     

     6.6% (1)(2)

    12  

     Type of Reporting Person (See Instructions)

     

     IA

     

    (1)

    Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. See Item 2 for more information.

    (2)

    Based upon 9,149,470 shares of Common Stock, outstanding as of November 12, 2024, as disclosed in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, filed on November 12, 2024 by the Issuer with the U.S. Securities and Exchange Commission.


    SCHEDULE 13G

    CUSIP No. 451033708

     

     1   

     Names of Reporting Persons

     

     Neil Shahrestani

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     Sec Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     599,913 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     599,913 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     599,913 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

     ☐

    11  

     Percent of class represented by amount in row (9)

     

     6.6% (1)(2)

    12  

     Type of Reporting Person (See Instructions)

     

     IN; HC

     

    (1)

    Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. See Item 2 for more information.

    (2)

    Based upon 9,149,470 shares of Common Stock, outstanding as of November 12, 2024, as disclosed in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, filed on November 12, 2024 by the Issuer with the U.S. Securities and Exchange Commission.


    Item 1.

     

      (a)

    Name of Issuer:

    iBio, Inc., a Delaware corporation (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    600 Madison Avenue, Suite 1601, New York, NY, 10022

     

    Item 2.

     

    (a)

    Name of Person Filing:

    This statement is filed jointly by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company (“Ikarian Capital”), and Neil Shahrestani (together referred herein as the “Reporting Persons”). Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the “Fund”), and certain separately managed accounts managed by Ikarian Capital (collectively, the “Managed Accounts”) are the record owners of the securities covered by this statement. Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts, and may be deemed to have beneficial ownership of the securities covered by this statement through the investment discretion it has over the Fund and the Managed Accounts. Ikarian Capital is ultimately controlled, indirectly, by Mr. Shahrestani. Accordingly, Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts. The Managed Accounts disclaim beneficial ownership of the shares held by the Fund.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.

     

    (c)

    Citizenship:

    See Item 4 on the cover page(s) hereto.


    (d)

    Title and Class of Securities:

    Common Stock

     

    (e)

    CUSIP No.:

    451033708

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)    ☒    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☒    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.

    Ownership

    The information set forth in Item 2(a) is incorporated by reference herein.

     

    (a)

    Amount Beneficially Owned as of November 14, 2024: See Item 9 on the cover pages(s) hereto.

     

    (b)

    Percent of Class as of November 14, 2024: See Item 11 on the cover page(s) hereto.

     

    (c)

    As of November 14, 2024, number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    The information set forth in Item 2(a) is incorporated by reference herein.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

    IKARIAN CAPITAL, LLC
    By:   /s/ Neil Shahrestani
      Neil Shahrestani, Sole Manager
    NEIL SHAHRESTANI
    /s/ Neil Shahrestani


    EXHIBIT INDEX

     

    Exhibit

      

    Description of Exhibit

    99.1    Joint Filing Agreement (filed herewith).

     

    Get the next $IBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iBio Announces Pricing of $50 Million Public Offering

    SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the "offering") of (i) pre-funded warrants to purchase 71,540,000 shares of iBio's common stock (the "pre-funded warrants"), and (ii) accompanying Series G warrants representing the right to purchase (the "Series G warrants") (a) 35,770,000 shares of iBio's common stock, or pre-funded warrants in lieu thereof, and (b) Series H warrants representing the right to purchase 35,770,000 shares of iBio's common stock, or pre-funded warrants in lieu thereof (the "Series H warrants"). The combined public offeri

    8/19/25 8:01:18 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Announces Proposed Public Offering

    SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the "offering") of (i) pre-funded warrants to purchase shares of iBio's common stock, and (ii) accompanying Series G warrants each representing the right to purchase (a) a fraction of a share of iBio's common stock, or a pre-funded warrant in lieu thereof, and (b) Series H warrants each representing the right to purchase a fraction of a share of iBio's common stock, or a pre-funded warrant in lieu thereof. All of the securities to be sold in the proposed offering will be offered by iBio. The proposed

    8/18/25 4:01:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

    Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake

    6/24/25 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on iBio with a new price target

    Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

    5/28/24 7:42:07 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on iBio with a new price target

    JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50

    11/29/21 7:34:24 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on iBio with a new price target

    JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50

    11/29/21 7:32:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Banjak Marc

    4 - iBio, Inc. (0001420720) (Issuer)

    2/24/25 6:01:30 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Duran Felipe

    4 - iBio, Inc. (0001420720) (Issuer)

    2/24/25 6:00:59 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Brenner Martin

    4 - iBio, Inc. (0001420720) (Issuer)

    2/24/25 6:00:12 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    SEC Filings

    View All

    iBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    8/21/25 4:11:41 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by iBio Inc.

    424B5 - iBio, Inc. (0001420720) (Filer)

    8/21/25 4:07:10 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    8/18/25 4:24:08 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:37 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:02 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:33:31 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Leadership Updates

    Live Leadership Updates

    View All

    iBio to Begin Trading on the Nasdaq Stock Exchange

    SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

    2/19/25 4:05:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Strengthens Board with Appointment of Two New Independent Directors

    SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

    11/25/24 8:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Reports Fiscal First Quarter 2025 Financial Results

    SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

    11/12/24 4:05:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by iBio Inc.

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    11/14/24 4:48:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by iBio Inc. (Amendment)

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    4/9/24 5:22:43 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Financials

    Live finance-specific insights

    View All

    iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

    Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake

    6/24/25 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

    Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibo

    6/23/25 4:15:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

    – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

    3/27/24 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care